$47m in revenue$46m in cash costs before depreciationyou do the maths - this company is doomed even with all their reserve upgrades
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential